Data / Drug companies / Ohm Laboratories Inc.
Ohm Laboratories Inc.: 38 products in the FDA NDC directory, labeler code 51660
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Ohm Laboratories Inc. (labeler code 51660) lists 38 products in the FDA National Drug Code Directory, covering 18 finished drugs by generic name. By type: 31 over the counter drugs, 5 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.
The request: Watch Ohm Laboratories Inc. (FDA labeler code 51660): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51660
- Products in commercial distribution
- 38
- Packages
- 85
- Finished drugs by generic name
- 18
- Prescription products
- 5
- Over the counter products
- 31
- Flagged as original packager
- 31 of 31 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- February 1, 1993
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 36 | 94.7% |
| Drugs for further processing | 2 | 5.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 31 | 81.6% |
| Prescription drugs | 5 | 13.2% |
| Drugs for further processing | 2 | 5.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Loratadine | 7 | 125 |
| Valsartan | 4 | 38 |
| Levonorgestrel | 4 | 31 |
| Guaifenesin | 2 | 123 |
| Loratadine and pseudoephedrine | 2 | 7 |
| Pseudoephedrine hydrochloride | 2 | 23 |
| Cetirizine hydrochloride | 2 | 119 |
| Guaifenesin and pseudoephedrine hcl | 2 | 14 |
| Guaifenesin and dextromethorphan hbr | 2 | 26 |
| Esomeprazole magnesium | 1 | 77 |
| Loperamide hcl and simethicone | 1 | 1 |
| Fexofenadine hydrochloride and pseudoephedrine hydrochloride | 1 | 16 |
| Fexofenadine hydrochloride | 1 | 65 |
| Cetirizine hydrochloride and pseudoephedrine hydrochloride | 1 | 10 |
| Loperamide hydrochloride | 1 | 82 |
| Ibuprofen and pseudoephedrine hydrochloride | 1 | 6 |
| Omeprazole | 1 | 106 |
| Ezetimibe | 1 | 26 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 11 | 28.9% |
| Tablet, extended release | 9 | 23.7% |
| Tablet, film coated | 6 | 15.8% |
| Tablet, chewable | 6 | 15.8% |
| Tablet, film coated, extended release | 2 | 5.3% |
| Capsule, delayed release | 1 | 2.6% |
| Tablet, sugar coated | 1 | 2.6% |
| Tablet, orally disintegrating | 1 | 2.6% |
| Tablet, delayed release | 1 | 2.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| My After Plan | 51660-098 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| My Choice | 51660-096 | Tablet | Generic drugs (ANDA) | May 1, 2026 |
| Dye-free loratadine | 51660-755 | Tablet, chewable | Generic drugs (ANDA) | December 2, 2025 |
| Cetirizine hydrochloride | 51660-939 | Tablet | Drugs for further processing | November 28, 2024 |
| Loratadine | 51660-526 | Tablet | Drugs for further processing | November 28, 2024 |
| Dye-free childrens loratadine | 51660-726 | Tablet, chewable | Generic drugs (ANDA) | March 15, 2024 |
| Cetirizine Hydrochloride | 51660-066 | Tablet, chewable | Generic drugs (ANDA) | July 21, 2022 |
| Fexofenadine hydrochloride | 51660-998 | Tablet, film coated | Generic drugs (ANDA) | April 29, 2022 |
| Guaifenesin | 51660-567 | Tablet, extended release | Generic drugs (ANDA) | April 1, 2022 |
| Guaifenesin | 51660-566 | Tablet, extended release | Generic drugs (ANDA) | April 1, 2022 |
| Loperamide HCl and Simethicone | 51660-069 | Tablet | Generic drugs (ANDA) | January 13, 2022 |
| Guaifenesin and Dextromethorphan HBr | 51660-301 | Tablet, extended release | Generic drugs (ANDA) | July 1, 2021 |
| Guaifenesin and Dextromethorphan HBr | 51660-110 | Tablet, extended release | Generic drugs (ANDA) | July 1, 2021 |
| Guaifenesin and Pseudoephedrine HCl | 51660-077 | Tablet, extended release | Generic drugs (ANDA) | April 1, 2021 |
| Guaifenesin and Pseudoephedrine HCl | 51660-074 | Tablet, extended release | Generic drugs (ANDA) | April 1, 2021 |
| Dye-Free Childrens Loratadine | 51660-112 | Tablet, chewable | Generic drugs (ANDA) | August 19, 2020 |
| Esomeprazole | 51660-027 | Capsule, delayed release | Generic drugs (ANDA) | August 14, 2020 |
| Omeprazole | 51660-029 | Tablet, delayed release | Generic drugs (ANDA) | June 1, 2019 |
| Childrens Loratadine | 51660-754 | Tablet, chewable | Generic drugs (ANDA) | June 30, 2018 |
| Loratadine | 51660-753 | Tablet, chewable | Generic drugs (ANDA) | June 1, 2018 |
| Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride | 51660-037 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 1, 2018 |
| Levonorgestrel | 51660-999 | Tablet | Generic drugs (ANDA) | November 1, 2017 |
| Levonorgestrel | 51660-723 | Tablet | Generic drugs (ANDA) | November 1, 2017 |
| Loratadine Allergy Relief | 51660-526 | Tablet | Generic drugs (ANDA) | November 1, 2017 |
| Ezetimibe | 51660-200 | Tablet | Generic drugs (ANDA) | June 12, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.